Startup · $10m raised
Melbourne, VIC
Every investor coverage indicates participated in a round Ankere Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon Capital | Seed | - |
| IP Group Australia | Seed | - |
Companies Ankere Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Associate Professor Bernard Flynn | Founder | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
| Dr Melissa McBurnie | Director | Brandon Capital portfolio, Brandon BioCatalyst portfolio, Startup Daily |
| Dr Siro Perez | Director | Brandon Capital portfolio, Brandon BioCatalyst portfolio, Startup Daily |
| Professor Stuart Pitson | Chief Scientific Officer · Founder | @AuManufacturing, Brandon Capital portfolio, Brandon BioCatalyst portfolio, Startup Daily |
| Professor Bernard Flynn | CEO and Research Director · Founder | @AuManufacturing, Brandon Capital portfolio, Brandon BioCatalyst portfolio, Startup Daily |
Stories naming Ankere Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of Australian manufacturing items: Manildra draws on CEFC money to quit coal, Ankere Therapeutics launches with seed backing, Micro-X gear reaches Ukraine, plus a vessel naming, precinct tenders, an FFI appointment and a cable rebrand.
Biotech startup Ankere Therapeutics launches with a $10 million seed round co-led by IP Group and Brandon Capital to develop inflammatory lung disease therapies, building on research from Monash and UniSA scientists.
Also Brandon Capital portfolio·Startup Daily·@AuManufacturing